Table 5.
Radiation-related effects and cosmetic evaluation
| Features | Total, n (%) | AMBI, n (%) | A-PHDRBT-boost, n (%) | χ2, p-value | |
|---|---|---|---|---|---|
| Symmetry | 0.021 | ||||
| Symmetry | 19 (52.8) | 15 (62.5) | 4 (33.3) | ||
| Acceptable difference | 11 (30.6) | 8 (33.3) | 3 (25) | ||
| Obvious difference | 2 (5.6) | 1 (4.16) | 1 (8.3) | ||
| Marked difference | 4 (11.1) | 0 (0) | 4 (33.3) | ||
| Retraction | 0.001 | ||||
| Not visible | 28 (77.8) | 23 (95.8) | 5 (41.6) | ||
| Slightly visible | 5 (13.9) | 1 (4.16) | 4 (33.3) | ||
| Obvious | 3 (8.3) | 0 (0) | 3 (25) | ||
| Marked | 0 (0) | 0 (0) | 0 (0) | ||
| Hyperpigmentation | 0.345 | ||||
| Not visible | 19 (52.8) | 14 (58.3) | 5 (41.6) | ||
| Slightly visible | 17 (47.2) | 10 (41.6) | 7 (58.3) | ||
| Obvious | 0 (0) | 0 (0) | 0 (0) | ||
| Marked | 0 (0) | 0 (0) | 0 (0) | ||
| Catheter puncture marks | 0.745 | ||||
| Not visible | 21 (58.3) | 13 (54.1) | 8 (66.6) | ||
| Slightly visible | 12 (33.3) | 9 (37.5) | 3 (25) | ||
| Obvious | 3 (8.3) | 2 (8.3) | 1 (8.3) | ||
| Marked | 0 (0) | 0 (0) | 0 (0) | ||
| Skin telangiectasia | 0.531 | ||||
| Not visible | 32 (88.9) | 21 (87.5) | 11 (91.6) | ||
| Slightly visible | 2 (5.6) | 1 (4.1) | 1 (8.3) | ||
| Obvious | 2 (5.6) | 2 (8.3) | 0 (0) | ||
| Marked | 0 (0) | 0 (0) | 0 (0) | ||
| Skin-subcutaneous atrophy or fibrosis | 0.589 | ||||
| Not visible | 17 (47.2) | 11 (45.8) | 6 (50) | ||
| Slightly visible | 17 (47.2) | 11 (45.8) | 6 (50) | ||
| Obvious | 2 (5.3) | 2 (8.3) | 0 (0) | ||
| Marked | 0 (0) | 0 (0) | 0 (0) | ||
| Oil cyst | 12 (33) | 8 (33.3) | 4 (33.3) | ||
| Fat necrosis | 11 (30) | 7 (29.2) | 4 (33.3) | ||
| Symptomatic fat necrosis | 1 (2.8) | 1 (4.2) | 0 (0) | ||
| Cosmetic outcomes | |||||
| Wazer’s criteria | 0.022 | ||||
| Excellent | 22 (61.1) | 18 (75) | 4 (33.3) | ||
| Good | 9 (25) | 5 (20.8) | 4 (33.3) | ||
| Fair | 5 (13.9) | 1 (4.1) | 4 (33.3) | ||
| Poor | 0 (0) | 0 (0) | 0 (0) | ||
AMBI – accelerated minimal breast irradiation, A-PHDRBT-boost – anticipated peri-operative high-dose-rate brachytherapy boost